IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v36y2018i8d10.1007_s40273-018-0649-y.html
   My bibliography  Save this article

Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence

Author

Listed:
  • Didik Setiawan

    () (University of Groningen
    University of Muhammadiyah Purwokerto)

  • Abrham Wondimu

    () (University of Groningen
    University of Groningen, University Medical Center Groningen (UMCG))

  • KohJun Ong

    (Centre for Infectious Disease Surveillance and Control, National Infection Service, Public Health England)

  • Albert Jan Hoek

    (London School of Hygiene and Tropical Medicine)

  • Maarten J. Postma

    (University of Groningen
    University of Groningen, University Medical Center Groningen (UMCG)
    University of Groningen)

Abstract

Background Men who have sex with men require special attention for human papillomavirus vaccination given elevated infection risks and the development of, in particular, anal cancer. Objective Our purpose was to review the cost effectiveness of human papillomavirus vaccination for both currently vaccine-eligible and non-eligible individuals, particularly the men-who-have-sex-with-men population, and synthesize the available evidence. Methods We systematically searched for published articles in two main databases (PubMed and EMBASE). Screening and data extraction were performed by two independent reviewers. The risk of bias was assessed using a validated instrument (Bias in Economic Evaluation, ECOBIAS). Methodological aspects, study results, and sensitivity analyses were extracted and synthesized to generate a consistent overview of the cost effectiveness of human papillomavirus vaccination in the men-who-have-sex-with-men population. Results From 770 identified articles, four met the inclusion criteria. Across the studies, human papillomavirus vaccination showed incremental cost-effectiveness ratios ranging from dominant to US$96,146 and US$14,000 to US$18,200 for tertiary prevention and primary prevention, respectively. The incremental cost-effectiveness ratio seemed most sensitive to vaccine efficacy, vaccine costs, and the incidence of anal cancer in the selected target populations. Conclusion This review presents the human papillomavirus vaccine, both as a primary and adjuvant (tertiary) vaccination, as a potentially cost-effective strategy for preventing mainly—but not limited to only—anal cancer in men-who-have-sex-with-men populations.

Suggested Citation

  • Didik Setiawan & Abrham Wondimu & KohJun Ong & Albert Jan Hoek & Maarten J. Postma, 2018. "Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence," PharmacoEconomics, Springer, vol. 36(8), pages 929-939, August.
  • Handle: RePEc:spr:pharme:v:36:y:2018:i:8:d:10.1007_s40273-018-0649-y
    DOI: 10.1007/s40273-018-0649-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-018-0649-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Thesis Thursday: Koh Jun Ong
      by Chris Sampson in The Academic Health Economists' Blog on 2020-01-16 07:00:00

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:36:y:2018:i:8:d:10.1007_s40273-018-0649-y. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Sonal Shukla) or (Springer Nature Abstracting and Indexing). General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.